Stemgent is an American privately funded biotech company focused on providing reagents and technology developed by some of the world's leading stem cell scientists. Founded in 2008, Stemgent has two fully operational facilities in both San Diego, California and Cambridge, Massachusetts. Stemgent currently has 40 employees.The company is designed to serve researchers who study stem cell biology and regenerative medicine and those who use cells derived from stem cells as tools to advance their understanding of major diseases. Wikipedia.
Stemgent | Date: 2014-12-11
The invention relates to pluripotent stems cells and their methods of use. The invention also relates to methods of producing pluripotent stem cells.
News Article | March 3, 2010
Stemgent, a provider of biological materials for life sciences research with offices in Cambridge, MA, and San Diego, reports this morning it will invest $4.5 million over the next three years in the Dundee, Scotland-based biotech firm Ubiquigent. Ubiquigent is producing biological products developed by the Scottish Institute for Cell Signalling at the University of Dundee. Stemgent is handling initial marketing of the fledgling Scottish biotech’s products in the U.S. market.
News Article | February 1, 2012
Stemgent advances stem cell science by providing proprietary reagents and tools developed and proven for reproducibility by some of the world’s leading stem cell scientists.
News Article | June 30, 2015
YOKOHAMA, Japan--(BUSINESS WIRE)--We are pleased to announce that Stemgent Inc. (Cambridge, MA), a ReproCELL Group Company (Yokohama, Japan - JASDAQ: 4978) has launched its new Stemgent StemRNA™-SR Reprogramming Kit, the first commercially available RNA reprogramming kit applicable to cellular reprogramming of a blood-derived cell type. This non-viral, non-DNA reprogramming kit combines self-replicative RNA (srRNA) and microRNA technology, providing stem cell researchers with a safe, flexible and cost-effective cellular reprogramming method applicable to both human fibroblasts and blood-derived endothelial progenitor cells (EPCs). EPCs are uniquely genetically stable and can be efficiently established from fresh or cryopreserved human peripheral and cord blood. This latest innovation is being unveiled at the 13th Annual Meeting of the International Society for Stem Cell Research (ISSCR), June 24 – 27 in Stockholm, Sweden. “The combination of readily-available patient blood samples with integration-free RNA reprogramming technology supported by the Stemgent StemRNA-SR Reprogramming Kit and protocol is a great step forward for researchers developing clinically relevant iPS cell lines” said Joseph Gentile (Chief Executive Officer, Stemgent). Stemgent is engaged in working alongside some of the world’s leading stem cell scientists in developing innovative technology and application solutions for the advancement of stem cell research. Its mission is to help simplify and support cellular reprogramming research by producing products being designed by leading stem cell researchers worldwide. Stemgent stem cell reagents are available to customers worldwide. For more information, visit: www.stemgent.com.
Chen H.-Y.,University of Rochester |
Yang Y.M.,University of Rochester |
Yang Y.M.,Stemgent |
Stevens B.M.,University of Rochester |
Noble M.,University of Rochester
EMBO Molecular Medicine | Year: 2013
We found that basal-like breast cancer (BLBC) cells use Cdc42 to inhibit function of the redox/Fyn/c-Cbl (RFC) pathway, which normally functions to convert small increases in oxidative status into enhanced degradation of c-Cbl target proteins. Restoration of RFC pathway function by genetic or pharmacological Cdc42 inhibition enabled harnessing of pro-oxidant effects of low μM tamoxifen (TMX) concentrations - concentrations utilized in trials on multiple tumour types - to suppress division and induce death of BLBC cells in vitro and to confer TMX sensitivity in vivo through oestrogen receptor-α-independent mechanisms. Cdc42 knockdown also inhibited generation of mammospheres in vitro and tumours in vivo, demonstrating the additional importance of this pathway in tumour initiating cell (TIC) function. These findings provide a new regulatory pathway that is subverted in cancer cells, a novel means of attacking TIC and non-TIC aspects of BLBCs, a lead molecule (ML141) that confers sensitivity to low μM TMX in vitro and in vivo and also appear to be novel in enhancing sensitivity to a non-canonical mode of action of an established therapeutic agent. Restoration of the redox/Fyn/c-Cbl pathway via suppression of Cdc42 function in basal-like breast cancer (BLBC) cells and tumours confers tamoxifen sensitivity in vitro and in vivo. © 2013. Source